ClinicalTrials.gg
CompletedNCT02183324Updated Dec 28, 2017

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Low dose of BI 1356 BS and Medium dose of BI 1356 BS in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-12-28.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Enrollment
74th of 96
72 · median 302
Started
2007
with 3 others
Phase 2
18 of 130
none open now
Registered
85th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 74th largest by enrollment of the 96 interventional ones that give a count, is one of 4 that started in 2007, is one of 18 in phase 2, and was the 85th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese patients with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese patients with a diagnosis of type 2 diabetes mellitus treated with diet and/or exercise only or with one or two oral hypoglycaemic agents except glitazones
  • Glycosylated A1 ()

    • \<= 8.5% at screening for patients treated with diet and/or exercise and/or one oral hypoglycaemic agent or
    • \<= 8.0% at screening for patients treated with two oral hypoglycaemic agents
  • Age ≥21 and ≤ 70 years
  • ≥ 17.6 and ≤ 35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination including blood pressure, pulse rate and (ECG) deviating from normal and of not acceptable clinical relevance
  • concomitant diseases like renal insufficiency, cardiac insufficiency ( II-IV), known cardiovascular diseases including hypertension (>150/95 mmHg), stroke, and (TIA).
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, except for type 2 diabetes mellitus, hyperlipidaemia and medically treated hypertension
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders except polyneuropathy
  • Chronic or relevant acute infections (e.g., (HIV), hepatitis)
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug before drug administration except anti-hypertensives, acetylsalicylic acid, and statins
  • Use of drugs decreasing blood glucose within 10 days before drug administration
  • Participation in another trial with an drug within two months before drug administration
  • Alcohol abuse
  • Drug abuse
  • Blood donation (100 mL or more within four weeks before drug administration)
  • Excessive physical activities (within one week before drug administration or during the trial)
  • Any laboratory value outside the reference range and the clinical relevance is not acceptable (or the value is more than three times higher than the , e.g., liver enzymes such as (AST(serum glutamate oxaloacetate transaminase/ SGOT)), alanine transaminase (ALT(serum glutamate pyruvate transaminase/ SGPT)), alkaline phosphatase (γALP), and lactate dehydrogenase (LDH)
  • Fasted blood glucose >240 mg/dL (=13.3 mmol/L) on two consecutive days during washout
  • Serum creatinine above 1.3 mg/dL at screening
  • Pregnancy or patients and breast-feeding patients
  • Not willing to use adequate (condom use plus another form of contraception, e.g., spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Low dose of BI 1356 BS

    Drug: Low dose of BI 1356 BS

  • Experimental
    Medium dose of BI 1356 BS

    Drug: Medium dose of BI 1356 BS

  • Experimental
    High dose of BI 1356 BS

    Drug: High dose of BI 1356 BS

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugLow dose of BI 1356 BS
  • DrugMedium dose of BI 1356 BS
  • DrugHigh dose of BI 1356 BS
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Global assessment of tolerability by the investigator on a 4-point scale (good, satisfactory, not satisfactory and bad)

    Time frame: Day 43

  2. Number of patients with adverse events

    Time frame: Up to day 50

  3. Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate)

    Time frame: Up to day 50

  4. Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, and urinalysis)

    Time frame: Up to day 50

Secondary outcomes

  1. Maximum measured concentration of the analyte in plasma (Cmax) at different time points

    Time frame: Up to day 43

  2. Time from last dosing to the maximum concentration of the analyte in plasma (tmax) at different time points

    Time frame: Up to day 43

  3. Area under the concentration time curve of the analyte in plasma (AUC) at different time points

    Time frame: Up to day 43

  4. Amount of the analyte that is eliminated in urine (Ae) at different time points

    Time frame: Up to day 43

  5. Fraction of parent drug eliminated in urine (fe) at different time points

    Time frame: Up to day 43

  6. Renal clearance of the analyte (CLR) at different time points

    Time frame: Up to day 43

  7. Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

    Time frame: After the last dose on day 28 up to day 43

  8. Average concentration of the analyte in plasma at steady state (Cavg)

    Time frame: After the last dose on day 28 up to day 43

  9. Terminal half-life of the analyte in plasma at steady state (t1/2,ss)

    Time frame: After the last dose on day 28 up to day 43

  10. Terminal rate constant in plasma at steady state (λz,ss)

    Time frame: After last dose on day 28 up to day 43

  11. Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)

    Time frame: After last dose on day 28 up to day 43

  12. Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)

    Time frame: After last dose on day 28 up to day 43

  13. Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)

    Time frame: After last dose on day 28 up to day 43

  14. Predose concentration of the analyte in plasma (Cpre) at different time points immediately before administration of the Nth dose

    Time frame: Up to day 28

  15. Calculation of accumulation ratio of the analyte in plasma based on Cmax (RA,Cmax)

    Time frame: Up to day 43

  16. Calculation of accumulation ratio of the analyte in plasma based on AUCτ (RA,AUCτ)

    Time frame: Up to day 43

  17. Minimum dipeptidyl peptidase IV (DPP-IV) activity (Emin) at different time points

    Time frame: Up to day 43

  18. Time to reach minimum DPP-IV activity (tmin) at different time points

    Time frame: Up to day 43

  19. DPP-IV activity at different time points

    Time frame: Up to day 43

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007 and a primary completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Feb 2007
Primary completionActual
Jun 2007
Last update
Dec 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02183324
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Feb 2007
Primary completion
Jun 2007
Last update
Dec 28, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion